· Published by Health Canada · Official notice
This is duplicated text of a letter from Otsuka Canada Pharmaceutical Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
April 7, 2014
Dear Health Care Professional,
Please distribute to relevant Departments (Bone Marrow Transplant Center, Oncology, Hematology, Paediatrics, Pharmacy, Internal Medicine and Nursing) and other involved professional staff and post this notice in all relevant areas of your institution.
Subject: Potential for Particulate Matter in 10 mL vials of BUSULFEX® (busulfan) 6 mg/mL Injection (DIN 02240602)
Otsuka Canada Pharmaceutical Inc. in consultation with Health Canada would like to inform you of a potential risk of black particulate matter in vials of BUSULFEX® (busulfan) 6 mg/mL Injection. Black particulate matter has been found in one vial of BUSULFEX® (busulfan) distributed in the European Union market. The black particulate matter has been identified to be of silicone and stainless steel composition. The likely root cause has been identified and corrected. Although there have been no reported complaints for BUSULFEX® (busulfan) lots that have been distributed in Canada , there is a potential that BUSULFEX® (busulfan) lots on the Canadian market could be affected.
BUSULFEX® (busulfan) Injection is indicated for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation, including: acute lymphocytic leukemia, acute non-lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease, multiple myeloma, and myelodysplastic syndrome.1
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of particulate matter or other serious or unexpected adverse reactions in patients receiving BUSULFEX® (busulfan) 6 mg/mL Injection should be reported to Otsuka Canada Pharmaceutical Inc. or Health Canada.
Otsuka Canada Pharmaceutical Inc.
2250 Alfred Nobel Boulevard, Suite 301
Saint-Laurent, Quebec
H4S 2C9
Phone: 1-877-341-9245
Fax: 1-905-689-1465
To correct your mailing address or fax number, contact Otsuka Canada Pharmaceutical Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Phone: 1-800-267-9675
Fax: 1-613-946-5636
To report any product quality complaints, or should you have any questions or need additional information about BUSULFEX® (busulfan), please contact Otsuka Canada Pharmaceutical Inc. Medical Information at 1-877-341-9245.
Otsuka is committed to the highest ethical and safety standards and continues to monitor BUSULFEX® product complaints worldwide.
Sincerely,
original signed by
Otsuka Canada Pharmaceutical Inc.
Per:
Khalid Mezzi, MD, MBA
Director, Medical Affairs
1 BUSULFEX® (busulfan) [product monograph]. Saint-Laurent, Quebec: Otsuka Canada Pharmaceutical Inc.; January 2012.